Aleniglipron Pill Delivers 12% Weight Loss in Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Aleniglipron, an oral small-molecule GLP-1 pill, produced up to 12.1% body weight loss over 36 weeks in a randomized, double-blind phase II trial of 230 adults with obesity or overweight, versus a 0.5% change in the placebo group.
- Robert Kushner, MD, professor emeritus at Northwestern Medicine, co-authored the Nature Medicine study, which tested three doses across 38 U.S. medical centers: 45mg (−9.0%), 90mg (−10.7%) and 120mg (−12.1%) taken once daily with or without food.
- Aleniglipron is chemically synthesized rather than peptide-based, setting it apart from injectable GLP-1 drugs like Wegovy and Ozempic — a structure that Kushner said could allow easier large-scale manufacturing and combination with other medications.
- Side effects were generally mild to moderate gastrointestinal issues that became less frequent over time, with 10.4% of participants discontinuing treatment and no cases of drug-induced liver injury reported.
- Structure Therapeutics, which funded the work, is moving aleniglipron into a phase III trial with slower dose escalation aimed at improving tolerability.
Why it matters: If phase III succeeds, aleniglipron could become the first once-daily oral GLP-1 therapy competitive with Wegovy and Ozempic, bypassing the injection, refrigeration, and peptide-manufacturing bottlenecks that have limited supply. For the roughly 230-patient efficacy set already shown, the 9–12% weight reduction lands close to what injectable semaglutide delivers in a similar window.
Ask SkimNews
